THC suppressed an overactive immune response in mice by correcting dysregulated microRNA molecules that control inflammatory T cell development, revealing a precise molecular mechanism for its anti-inflammatory properties.
Read this if you are interested in the molecular mechanisms behind cannabis's anti-inflammatory effects.
THC corrected two specific microRNA dysregulations driving inflammatory T cell activation.
What the researchers found
Researchers induced a delayed-type hypersensitivity response in mice (an overactive immune reaction driven by Th1 and Th17 inflammatory T cells) and then treated them with THC. The treatment reduced swelling and immune cell infiltration at the site of inflammation.
THC decreased lymphocyte activation and reduced the development of both Th1 and Th17 inflammatory cell types, including their signature transcription factors and cytokines.
The molecular mechanism involved microRNA (miR), small molecules that regulate gene expression. The immune response caused an overexpression of miR-21 (which promotes Th17 cells) and a decrease in miR-29b (which normally suppresses the inflammatory cytokine interferon-gamma). THC reversed both of these microRNA changes.
When researchers directly manipulated these microRNAs in cells from immunized mice (inhibiting miR-21 or boosting miR-29b), they produced the same effects as THC treatment, confirming the mechanism.
Why it matters
This study identifies a precise molecular mechanism for THC's anti-inflammatory effects. Rather than just observing that THC reduces inflammation, it shows exactly how: by correcting the specific microRNA dysregulation that drives inflammatory T cell development. This level of mechanistic understanding could inform development of targeted anti-inflammatory therapies.
The numbers in context
THC dose: 20 mg/kg. THC reversed miR-21 overexpression and miR-29b downregulation. miR-21 inhibition increased SMAD7 (anti-inflammatory). miR-29b mimicry decreased interferon-gamma expression.
How the study worked
In vivo study using C57BL/6 mice with methylated BSA-induced delayed-type hypersensitivity. THC was administered at 20 mg/kg. Researchers measured swelling, immune cell infiltration, T cell activation, and Th1/Th17 lineage commitment. MicroRNA expression was quantified, and transfection experiments with miR-21 inhibitor and miR-29b mimic confirmed the mechanistic pathway.
What this study cannot tell us
Animal study using a single dose of THC in a specific immune challenge model. The microRNA mechanism demonstrated may not apply to all types of inflammation. The 20 mg/kg dose is relatively high and may not reflect typical human exposure. Translation to human autoimmune conditions requires further research.
How to read the evidence
Preliminary evidence from a well-designed animal study with mechanistic confirmation through transfection experiments, though human relevance remains to be established.
When this study was published
Published in 2016. MicroRNA-mediated immunomodulation is a growing area of both cannabis and immunology research.
The bigger picture
Autoimmune and inflammatory conditions affect millions of people, and current treatments often have significant side effects. Understanding exactly how THC modulates the immune response at the microRNA level could lead to more targeted anti-inflammatory drugs that capture cannabis's benefits without psychoactive effects.
Questions still open
- Do other cannabinoids (CBD, CBG) affect the same microRNA pathways? Would lower doses of THC produce the same microRNA corrections? Could synthetic miR-21 inhibitors or miR-29b mimics be developed as anti-inflammatory drugs inspired by this mechanism? Does chronic cannabis use alter baseline microRNA profiles in the immune system?
Common questions
How does THC reduce inflammation?
Could this lead to new anti-inflammatory drugs?
Read the original research
Marijuana-derived Δ-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation.
Journal of molecular medicine (Berlin, Germany), 94(9), 1039-51
Citation
Sido, Jessica M; Jackson, Austin R; Nagarkatti, Prakash S; Nagarkatti, Mitzi. (2016). Marijuana-derived Δ-9-tetrahydrocannabinol suppresses Th1/Th17 cell-mediated delayed-type hypersensitivity through microRNA regulation.. Journal of molecular medicine (Berlin, Germany), 94(9), 1039-51. https://doi.org/10.1007/s00109-016-1404-5
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk